Clal Biotechnology reported ILS-857K in Gross Profit on Sales for its fiscal quarter ending in June of 2022.





Gross Profit On Sales Change Date
Arca Biopharma 0 0 Mar/2025
aTyr Pharma USD 190K 15.57M Sep/2025
Cara Therapeutics USD 2.57M 1.11M Mar/2025
Clal Biotechnology ILS -857K 1.42M Jun/2022
Compugen USD 241K 649K Sep/2025
Immunic 0 0 Mar/2025
Infinity Pharmaceuticals USD 231K 59K Jun/2023
Minerva Neurosciences -4.27M 26.79M Dec/2024
RedHill Biopharma USD 584K 0 Jun/2024
TherapeuticsMD USD 234K 79K Jun/2024